Nicaise Claude 4

What Happened

• Claude Nicaise, a director of Sarepta Therapeutics, was granted 16,875 restricted stock units (RSUs) on June 4, 2026 (transaction code A — award). The Form 4 lists the per-share price as N/A; no cash value or total dollar amount is provided on the filing. Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely filing).
• Grant type/code: A (award/grant of RSUs).
• Quantity: 16,875 RSUs granted.
• Price/Value: N/A on the filing (no dollar amount reported).
• Shares owned after transaction: Not disclosed in the provided Form 4.
• Footnote: F1 — RSUs vest on the earlier of the one‑year anniversary of the grant or the next annual meeting of stockholders that is at least 50 weeks after the prior year’s meeting.
• No 10b5-1 plan, tax-withholding, or other special codes were reported in the supplied details.

Context

• RSU grants to directors are a common form of equity compensation and do not represent an immediate open‑market purchase or sale — they convert into actual shares only upon vesting. This disclosure is informational about compensation rather than an expressed buy/sell decision by the insider.